Electroencephalographic abnormalities associated with antidepressant treatment: a comparison of mirtazapine, venlafaxine, citalopram, reboxetine, and amitriptyline.
Andrea
A
Sterr
Frank
F
Padberg
Benedikt
B
Amann
Roland
R
Mergl
Christoph
C
Mulert
Georg
G
Juckel
Ulrich
U
Hegerl
Oliver
O
Pogarell
D000328:Adult; D000639:Amitriptyline / Q000009:adverse effects / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D002540:Cerebral Cortex / Q000187:drug effects / Q000503:physiopathology; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use; D004569:Electroencephalography / Q000187:drug effects* / Q000706:statistics & numerical data; D004827:Epilepsy / Q000139:chemically induced* / Q000175:diagnosis* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000523:psychology; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use; D000077593:Reboxetine; D000069470:Venlafaxine Hydrochloride
D000928:Antidepressive Agents; D003511:Cyclohexanols; D009025:Morpholines; D015283:Citalopram; D000639:Amitriptyline; D008803:Mianserin; D000069470:Venlafaxine Hydrochloride; D000077593:Reboxetine; D000078785:Mirtazapine